- Home
- OABI vs NBTX Comparison
OABI vs NBTX Comparison
Compare OABI & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OABI
- NBTX
- Stock Information
- Founded
- OABI 2012
- NBTX 2003
- Country
- OABI United States
- NBTX France
- Employees
- OABI N/A
- NBTX N/A
- Industry
- OABI Biotechnology: Pharmaceutical Preparations
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- OABI Health Care
- NBTX Health Care
- Exchange
- OABI Nasdaq
- NBTX Nasdaq
- Market Cap
- OABI 185.9M
- NBTX 167.8M
- IPO Year
- OABI N/A
- NBTX 2020
- Fundamental
- Price
- OABI $1.38
- NBTX $4.58
- Analyst Decision
- OABI Strong Buy
- NBTX Strong Buy
- Analyst Count
- OABI 3
- NBTX 1
- Target Price
- OABI $7.00
- NBTX $8.00
- AVG Volume (30 Days)
- OABI 953.8K
- NBTX 9.8K
- Earning Date
- OABI 05-08-2025
- NBTX 04-02-2025
- Dividend Yield
- OABI N/A
- NBTX N/A
- EPS Growth
- OABI N/A
- NBTX N/A
- EPS
- OABI N/A
- NBTX N/A
- Revenue
- OABI $26,744,000.00
- NBTX N/A
- Revenue This Year
- OABI N/A
- NBTX N/A
- Revenue Next Year
- OABI $40.06
- NBTX $221.06
- P/E Ratio
- OABI N/A
- NBTX N/A
- Revenue Growth
- OABI 27.07
- NBTX N/A
- 52 Week Low
- OABI $1.22
- NBTX $2.76
- 52 Week High
- OABI $4.96
- NBTX $6.56
- Technical
- Relative Strength Index (RSI)
- OABI 39.15
- NBTX 74.39
- Support Level
- OABI $1.22
- NBTX $4.06
- Resistance Level
- OABI $1.42
- NBTX $4.20
- Average True Range (ATR)
- OABI 0.08
- NBTX 0.13
- MACD
- OABI 0.03
- NBTX 0.07
- Stochastic Oscillator
- OABI 39.02
- NBTX 79.29
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.